Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections

Clinical Pharmacokinetics

Volumn 44, Issue 3, 2005, Pages 305-316

  Isla, Arantxa ^a   Canut, Andrés ^b   Gascón, Alicia R ^a   Labora, Alicia ^b   Ardanza Trevijano, Bruno ^b   Solinís, Maria Ángeles ^a   Pedraz, Jose Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME AXETIL; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; MINOCYCLINE; PENICILLIN V; SPIRAMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; FUSOBACTERIA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PEPTOSTREPTOCOCCUS; PHARMACODYNAMICS; PREVOTELLA; PRIORITY JOURNAL; SIMULATION; TOOTH INFECTION;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BACTERIA; HUMANS; INFECTION; MICROBIAL SENSITIVITY TESTS; MOUTH; MOUTH DISEASES; TOOTH DISEASES;

EID: 16444367574     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544030-00006     Document Type: Article

References (72)

1. Ellen RP, McCulloch CA. Evidence versus empiricism: rational use of systemic antimicrobial agents for treatment of periodontitis. Periodontol 2000 1996; 10: 29-44
2. Longman LP, Preston AJ, Martin MV, et al. Endodontics in the adult patient: the role of antibiotics. J Dent 2000; 28 (8): 539-48
3. Kuriyama T, Karasawa T, Nakasawa K, et al. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90 (5): 600-8
4. Palmer NOA, Martin MV, Pealing R, et al. Antibiotic prescribing knowledge of National Health Service general dental practitioners in England and Scotland. J Antimicrob Chemother 2001; 47 (2): 233-7
5. Jaunay T, Sambrook P, Goss A. Antibiotic prescribing practices by South Australian general dental practitioners. Aust Dent J 2000; 45 (3): 179-86
6. Roy K, Bagg J. Antibiotic prescribing by general dental practitioners in the Greater Glasgow Health Board, Scotland. Br Dent J 2000; 188 (12): 674-6
7. Dupon M, Cohere-Moleres MF, Dupon C, et al. Evaluation of antibiotherapy in dental surgery [in French]. Presse Med 1994; 23 (39): 1803-8
8. Yingling NM, Byrne BE, Hartwell GR. Antibiotic use by members of the American Association of Endodontists in the year 2000: report of national survey. J Endod 2002; 28 (5): 396-404
9. Dailey YM, Martin MV. Are antibiotics being used appropriately for emergency dental treatment? Br Dent J 2001; 191 (7): 391-3
10. Rehan HS, Singh C, Tripathi CD, et al. Study of drug utilization pattern in dental OPD at tertiary care teaching hospital. Indian J Dent Res 2001; 12 (1): 51-6
11. Caspar L, Vago P. The tendency of antibiotic therapy in dental and oral surgical practice [in Hungarian]. Fogorv Sz 1998; 91 (3): 67-78
12. Schentag JJ, Swanson DJ, Smith IL. Dual individualization: antibiotic dosage calculation from the integration of in vitro pharmacodynamics and in vivo pharmacokinetics. J Antimicrob Chemother 1985; 15 Suppl. A: 47-57
13. Sánchez Navarre A, Sánchez Recio MM. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation. Clin Pharmacokinet 1999; 37 (4): 289-304
14. Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11 (6); 426-39
15. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14 (2): 165-72
16. Ebert SC. Pharmacokinetic-pharmacodynamic modeling of irreversible drug effects. In: Derendorf H, Hochhaus G, editors. Handbook of pharmacokinetic/ pharmacodynamic correlation. New York: CRC Press, 1995: 35-56
17. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37 (1): 1-6
18. MacGowan AP, Bowker KE. Continuous infusion of β-lactam antibiotics. Clin Pharmacokinet 1998; 35 (5): 391-402
19. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother 1999; 11 (1): 11-27
20. Loza E, Morosini MI, Negri MC, et al. Estudio multicéntrico nacional de la actividad in vitro de moxifloxacino frente a patógenos respiratorios. Rev Esp Quimioter 2000; 13 (1): 37-43
21. Roche Y, Yoshimori RN. In vitro activity of spiramycin and metronidazole alone or in combination against clinical isolates from odontogenic abscesses. J Antimicrob Chemother 1997; 40 (3): 353-7
22. Hillier SL, Moncla BJ. Peptostreptococcus, Propionibacterium, Eubacterium, and other non-sporeforming anaerobic gram-positive bacteria. In: Murray PR, Baron EJ, Pfaller MA, et al., editors. Manual of clinical microbiology. 6th ed. Washington, DC: ASM Press, 1995: 587-602
23. Woodcock JM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41 (1): 101-6
24. Kuriyama T, Karasawa T, Nakasawa K, et al. Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections. Oral Microbiol Immunol 2002; 17 (2): 132-5
25. Matto J, Asikainen S, Vaisanen ML, et al. Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to select antimicrobial agents. Antimicrob Agents Chemother 1999; 43 (10): 2383-8
26. Appelbaum PC, Spangler SK, Jacobs MR. β-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavunanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 US centres. Antimicrob Agents Chemother 1990; 34 (8): 1546-50
27. Sbordone L, Barone A, Ramaglia L, et al. Antimicrobial susceptibility of periodontophatic bacteria associated with failing implants. J Periodontol 1995; 66 (1): 69-74
28. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 2001; 47 (1): 61-6
29. Ballow CH, Amsden GW, Highet VS, et al. Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers. Clin Drug Invest 1998; 15 (2): 159-67
30. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500 milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41 (10): 2256-60
31. Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42 (4): 885-8
32. Dan M, Yampolsky E, Poch F. Serum concentrations and ex vivo inhibitory/bactericidal activity of clindamycin after administration of two oral dosages. Chemotherapy 1997; 43 (4): 227-31
33. Deppermann KM, Lode H, Höffken G, et al. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989; 33 (11): 1901-7
34. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51 (3): 483-505
35. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm 1997; 54: (22): 2569-84
36. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32 (2): 101-19
37. Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990; 2 (3): 171-7
38. Frydman AM, Le Roux Y, Desnottes JF, et al. Pharmacokinetics of spiramycin in man. J Antimicrob Chemother 1988; 22 Suppl. B: 93-103
39. Gatti G, Flaherty J, Bubp J, et al. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother 1993; 37 (5): 1137-43
40. Ishii K, Saito Y, Itai S, et al. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev Ind Pharm 1998; 24 (2): 129-37
41. Jetlund O, Thurmann-Nielsen E, Walstad RA. Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy. Int J Clin Pharmacol Res 1991; 11 (1): 1-6
42. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38 (3): 243-70
43. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25 (5): 370-4
44. Lang CC, Moreland TA, Davey PG. Bioavailability of cefuroxime axetil: comparison of standard and abbreviated methods. J Antimicrob Chemother 1990; 25 (4): 645-50
45. Liu CM, Chen YK, Yang TH, et al. High-performance liquid Chromatographic determination of clindamycin in human plasma or serum: application to the bioequivalency study of clindamycin phosphate injections. J Chromatogr B 1997; 696 (2): 298-302
46. Macdonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973; 14 (5): 852-61
47. Mensa J, Gatell JM, Jiménez de Anta MT, et al. Guía de terapéutica antimicrobiana. 12th ed. Barcelona: Masson SA, 2001
48. Miglioli PA, Pivetta P, Strazzabosco M, et al. Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990; 39 (2); 161-4
49. Montoya MA, Girard ME, Torres S, et al. Relative bioavailability among metronidazole tablets [in Spanish]. Gac Med Mex 1988; 124 (1-2): 19-25
50. Nix DE, Symonds WT, Hyatt JM, et al. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor and cefuroxime axetil in healthy volunteers. Pharmacotherapy 1997; 17 (1): 121-5
51. Overbosch D, Mattie H, van Furth R. Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin. Br J Clin Pharmacol 1985; 19 (5): 657-68
52. Plaisance KI, Drusano GL, Forrest A, et al. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 1989; 33 (5): 618-20
53. Quiding H, Arwidsson HG, Grahn Hakansson EG, et al. Saliva-resistant coating of tablets prevents oral release of penicillin: plasma but not saliva equivalence. Eur J Clin Pharmacol 1998; 54 (9-10): 749-52
54. Reed M. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996; 15 (10): 949-54
55. Siegmund W, Zschiesche M, Franke G, et al. Bioavailability of metronidazole formulations (Vagimid®). Pharmazie 1992; 47 (7): 522-5
56. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15 (6): 355-66
57. Trampuz A, Wenk M, Rajacic Z, et al. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 2000; 44 (5): 1352-5
58. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29-36
59. Wise R, Bennet SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 1984; 13 (6): 603-10
60. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7 (11): 589-96
61. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard. 5th ed. Wayne (PA): National Committee for Clinical Laboratory Standards. 2000. Document M11-A4; 21 (2)
62. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 5th ed. Wayne (PA): National Committee for Clinical Laboratory Standards, 2000. Document M7-A5
63. Malizia T, Tejada MR, Ghelardi E. et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997; 68 (12): 1206-9
64. Blandizzi C, Malizia T, Lupetti A. et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999; 70 (9): 960-6
65. Calatayud J, Martínez-Sicilia A, Lucas M. Revisión de la clindamicina. Av Odontoestomatol 1988; 8: 397-402
66. Denks A, Plagmann HC, Lange DE. Concentration and determination of spiramycin in gingiva and saliva [in German]. Dtsch Zahnärztl Z 1972; 27 (4): 336-40
67. Ciancio SG, Mather ML, McMullen JA. An evaluation of minocycline in patients with periodontal disease. J Periodontol 1980; 51 (9): 530-4
68. Van Oosten MA, Notten FJ, Mikx FH. Metronidazole concentrations in human plasma, saliva and gingival crevice fluid after a single dose. J Dent Res 1986; 65 (12): 1420-3
69. Britt MR, Pohlod DJ. Serum and crevicular concentrations after a single oral dose of metronidazole. J Periodontol 1986; 57 (2): 104-7
70. Sefton AM, Maskell JP, Beighton D, et al. Azithromycin in the treatment of periodontal disease: effect on microbial flora. J Clin Periodontol 1996; 23: 998-1003
71. Gattis WA. A selected review of antimicrobial concentrations within tissues of the bone, eye, and lung. Antimicrob Infect Dis Newslett 1994; 13: 75-86
72. Prieto J, Gómez-Lus ML. Tratamiento de las infecciones bucodentarioas. In: Dronbic L, editor. Tratamiento antimicrobiano. Madrid; Ergon, 2002: 497-503